Tamoxifen Citrate in Treating Patients With Metastatic or Recurrent Breast Cancer
Status:
Active, not recruiting
Trial end date:
2023-05-31
Target enrollment:
Participant gender:
Summary
RATIONALE: Estrogen can cause the growth of breast cancer cells. Hormone therapy using
tamoxifen citrate may fight cancer by blocking the use of estrogen by tumor cells.
PURPOSE: This phase II trial is studying how well tamoxifen citrate works in patients with
metastatic or recurrent breast cancer.